Bristol Myers Squibb stock adds AI angle through Pathos deal
Published on 11/03/2026 at 15:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Strategy Gains A New AI Layer
- Bristol Myers Squibb led Pathos AI's 237 million US dollar Series E financing.
- The collaboration gives Bristol Myers Squibb three-year exclusive rights for neuroscience applications of Pathos Foundry.
- The investment adds artificial intelligence and longitudinal patient data to the company's Alzheimer’s research strategy.
Bristol Myers Squibb is adding Pathos AI to its research strategy as the pharmaceutical company seeks to strengthen drug development in neuroscience and Alzheimer’s disease. Pathos said on October 23 that Bristol Myers Squibb led its 237 million US dollar Series E financing round.
AI Deal Broadens Research Options
The financing gives Bristol Myers Squibb access to Pathos Foundry across its broader research and development portfolio, while the company secured three-year exclusive rights for neuroscience development. Pathos said the platform combines specialized artificial intelligence agents with clinical, genomic and biological information to guide drug-program decisions.
The collaboration with Pathos and Tempus AI also covers a specialized longitudinal dataset for Alzheimer’s disease and other neurological conditions. Pathos will license the dataset from Tempus under a five-year, 55 million US dollar agreement, according to the Pathos announcement.
Pipeline Execution Remains Key
Pathos said the financing will support four active clinical assets, including JSKN016, a TROP2/HER3 bispecific antibody-drug conjugate headed toward registrational studies. For Bristol Myers Squibb, the neuroscience arrangement is intended to improve disease understanding, patient selection and clinical-trial design. It adds a technology and data component to a pipeline that remains central to the company's growth outlook.
Bristol Myers Squibb stock traded at 56.44 euros on Lang & Schwarz at 15:37 CET on Tuesday, November 3, 2026.
Investors can follow the real-time quote of Bristol Myers Squibb stock as the company advances its clinical and data strategy.
The S&P 500 provides the relevant US market backdrop for Bristol Myers Squibb, with current market reports available for the index.
More news and analyses on Bristol Myers Squibb stock will follow the next pipeline milestones and research updates.
Bristol Myers Squibb Facts
- Company: Bristol Myers Squibb
- ISIN: US1101221083
- Ticker: BMY
- Trading venue: Lang & Schwarz
- Quote: 56.44 euros on Tuesday, November 3, 2026, at 15:37 CET
